{"prompt": "['14', 'MC1488 WEE1', 'MCCC', 'The single-dose maximum tolerated dose (MTD) for both the gemcitabine and', 'cisplatin combination therapies was 200 mg of AZD1775 Dose-limiting', 'toxicities (DLTs) tended to be hematological in nature (i.e. leukopenia,', 'neutropenia and thrombocytopenia) in the gemcitabine group and constitutional', '(i.e. diarrhea and dehydration) in the cisplatin group. The single-dose MTD for', 'the combination with carboplatin was 325 mg of AZD1775. DLTs in this group', 'were related to serum chemistry.', 'Hematologic DLTs were most commonly observed in the multiple-dose', 'AZD1775 combination treatment groups with gemcitabine and cisplatin. An', 'MTD of AZD1775 in combination with gemcitabine was established with a dose', 'of 175 mg QD x 2 days during Week 1 with gemcitabine 1000 mg/m2 once', 'weekly for 3 consecutive weeks, every 4 weeks. Two DLTs (grade 3 febrile', 'neutropenia and grade 3 aspartate aminotransferase and alanine aminotransferase', '(AST/ALT) increase) were observed at 200 mg once daily for 2 days with the', 'regimen in combination with gemcitabine. The dose was adjusted to 175 mg once', 'daily for 2 days, and one DLT has been reported to date. The MTD for', 'combination with cisplatin has been exceeded at the 250 mg dose level, and', 'tolerability of the MTD at 200 mg BID has been confirmed. DLTs observed in', 'the multiple-dose carboplatin combination have been both hematological and', 'constitutional in nature. The multiple-dose MTD in combination with carboplatin', 'is AZD17751 225 mg BID.', 'The MTD for AZD1775 in combination with 5-FU was not reached due to early', 'study termination. DLTs of encephalopathy and hyponatraemia were observed in', 'the AZD1775 20 mg BID in combination with 1000 mg/m2 5-FU treatment', 'group.', 'Triplet-based therapy was administered in the study PN004 with AZD1775,', 'carboplatin, and paclitaxel. The starting dose of 225 mg AZD1775 (BID for 5', 'total doses) in Part 1 was generally well tolerated. One patient experienced a', 'DLT in the first six patients treated and the dose remained at 225 mg BID 2.5', 'days. A total of 15 patients were treated, with 3 DLTs being reported (grade 3', 'and 4 febrile neutropenia and grade 4 thrombocytopenia). The study expanded to', 'Part 2 and is ongoing. Other toxicities were generally blood and lymphatic', 'system disorders and gastrointestinal.', 'For the combination of AZD177: with topotecan plus cisplatin in study PN008,', 'toxicities were generally hematological and gastrointestinal in nature. No', 'unexpected toxicities were observed.', 'In study PN009 and the premarket formulation substudy to PN001 (both', 'combining 2.5-day BID dosing of AZD1775 with carboplatin) there were no', 'appreciable differences in toxicity from the ones observed in the carboplatin arm', 'of study PN001. However, increased hematological toxicity was observed, which', 'is considered to be a function of a drug-drug interaction with aprepitant (which', 'was administered as anti-nausea medication in these studies).']['15', 'MC1488 WEE1', 'MCCC', '1.42', 'Clinical Efficacy', 'In Study PN001, of 176 evaluable patients who received AZD1775 (either single or', 'multiple doses) as monotherapy or in combination with gemcitabine, cisplatin, or', 'carboplatin, a partial response (PR) (confirmed and unconfirmed) was observed in 17', '(9.7%) patients, and stable disease (SD) was observed in 94 (53.4%) patients. The table', 'below shows the efficacy outcome in Study PN001 by treatment arm.', 'Study PN001 Efficacy', 'Treatment', 'Dose', 'Patients', 'Patients Evaluable', 'PR*', 'SD', 'PD', 'NE', 'Frequency', 'Treated (N)', '[N (%)', '(N)', '(N)', '(N)', 'AZD1775 in', 'combination with', 'Single-dose', '14', '12 (85.7)', '1c', '8', '2', '1', 'gemcitabine', 'AZD1775 in', '1c', 'combination with', 'Single-dose', '13', '12 (92.3)', '7', '3', '1 u', 'cisplatin', 'AZD1775 in', '1 c', 'combination with', 'Single-dose', '16', '15 (93.8)', '3', '9', '1', '1 u', 'carboplatin', 'AZD1775 in', '1c', 'combination with', 'Multi-dose', '67', '55 (82.1)', '35', '17', '2 u', 'gemcitabine', 'AZD1775 in', '3c', 'combination with', 'Multi-dose', '45', '38 (84.4)', '16', '15', '4 u', 'cisplatin', 'AZD1775 in', 'combination with', 'Multi-dose', '46', '44 (95.6)', '2 u', '25', '16', 'carboplatin', '* confirmed and unconfirmed', 'NE=not evaluable, c=confirmed, u=unconfirmed', 'No complete or PRs were observed in either of Studies PN005 or PN008 at the time that they were', 'terminated.', '1.43', 'Clinical Pharmacokinetics and pharmacodynamics', 'Clinical Pharmacokinetics', 'The PK data of AZD1775 following a single oral administration showed a', 'moderate rate of absorption with a Tmax occurring at 3 to 4 hours. Post-peak', 'plasma concentrations declined essentially in a mono-exponential manner with', 'a', 't1/2 in the region of 10 hours. Exposure as measured by maximum plasma drug', 'concentration observed (Cmax) and area under the curve (AUC 0-00) increased in', 'a dose-proportional manner over the dose range of 325 to 1300 mg. The urinary', 'excretion of AZD1775 was investigated after single-oral-dose monotherapy at', '325, 650, and 1300 mg of AZD1775. The mean percent of total AZD1775']\n\n###\n\n", "completion": "END"}